MT-002

N/A

Report date: 2026/05/27 11:07:34
NMEFirst In Class

Base Information

Drug NameMT-002
Drug Alias NameMT-002
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionCalcitonin gene-related peptide modulatorsAnti-Pituitary adenylate cyclase-activating polypeptide
TargetsCalcitonin gene-related peptidePituitary adenylate cyclase-activating polypeptide
Therapy Area/IndicationsMigraine Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesParagon Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesParagon Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMigraine Disorders
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A